Missionomics Back to app

Healthcare

Sotera Health Company (SHC)

Healthcare $5.1B market cap

Data as of July 16, 2026

Environment
52.00
People
75.00
Leadership
68.00

Environment story

Sotera Health demonstrates significant environmental compliance challenges centered on ethylene oxide (EO) emissions and hazardous materials management. The company operates sterilization facilities using EO and Co-60, both of which carry material environmental and occupational health risks. While the company has invested in emission control enhancements and committed to comply with 2024 EPA NESHAP regulations by April 2026 (with a two-year exemption granted July 2025), the environmental score reflects substantial deductions for: (1) undisclosed Scope 1, 2, and 3 emissions data; (2) no disclosed net-zero target year or decarbonization roadmap; (3) ongoing EO litigation and regulatory scrutiny indicating historical non-compliance or perception of risk; (4) dependence on radioactive Co-60 sourced from Russian nuclear reactors (20% of supply, potentially 50% in given years), creating supply-chain carbon and political risk; and (5) decommissioning liabilities (~$50.3 million in financial assurance for radiological remediation). The company has made proactive facility enhancements but lacks transparency on lifecycle emissions, renewable energy adoption, or credible net-zero commitments. No evidence of greenwashing via offsets was detected; however, the absence of disclosed Scope 3 emissions (product-usage and supply-chain) combined with unresolved EO health claims results in a below-median environmental score.

Criticisms on file

  • Ethylene Oxide (EO) Tort Litigation – Ongoing Multi-State Claims. As of 2025, company defending lawsuits in California, Georgia, Illinois, and New Mexico alleging personal injury, property devaluation, and health impacts from EO emissions. Illinois Willowbrook facility: $408.0M settlement (2023, 880+ claims), $30.9M settlement (April 2025, 97 claims), $34.0M settlement (July 2025, 129 claims). Georgia Atlanta facility: $35.0M settlement (October 2023, 79 claims). Approximately 450 personal injury and 305 property devaluation claims remain pending in Georgia. First Illinois trial verdict awarded $358.7M judgment (including $320M punitive damages) against Sterigenics subsidiaries; second trial ruled in favor of defendants. Company denies allegations and maintains EO claims lack scientific merit.
    Source: SHC 10-K 2025; Note 19 Commitments and Contingencies; Item 3 Legal Proceedings
  • EPA EO Risk Assessment and Community Outreach. U.S. EPA 2016 IRIS Assessment identified potential increased cancer risk from EO exposure. EPA National Air Toxics Assessments identified EO as cancer concern in multiple areas including near SHC facilities. EPA conducted community outreach sessions near commercial EO facilities; such sessions have increased litigation risk and community resistance.
    Source: SHC 10-K 2025 Risk Factors: 'Potential health risks associated with the use of EO may subject us to future liability claims'
  • Santa Teresa, New Mexico Facility – Preliminary Injunction. June 2021: Court granted preliminary injunction prohibiting Sterigenics from allowing uncontrolled EO emissions. December 2021: Court established monitoring protocols. Facility operations continue under court-ordered compliance requirements.
    Source: SHC 10-K 2025 Risk Factors: 'Our operations are subject to a variety of business continuity hazards and risks'
  • Radioactive Material and Co-60 Contamination Risk. Company stores and transports Co-60 (double-encapsulated pencils); risk of corrosion, source leaks, and radioactive contamination requiring costly cleanup. Company currently provides $50.3M in financial assurance (letters of credit, surety bonds) for decommissioning liabilities. Potential for unplanned contamination and increased waste disposal costs.
    Source: SHC 10-K 2025 Risk Factors: 'Safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials'
  • South Coast Air Quality Management District (SCAQMD) Regulations. SCAQMD adopted new EO sterilization regulations December 2023, requiring compliance by September 2025. SCAQMD published new health risk assessment in 2024 and conducted community meetings about EO emission risks. Planned community meetings for Ontario, California facility (early 2026). Company expects capital costs for equipment enhancements and process automation.
    Source: SHC 10-K 2025 Risk Factors: 'We may be subject to evolving changes in environmental, health and safety regulations'
  • European Union Medical Devices Regulation – EO Sterilization. EU reviewing regulations for EO sterilization facilities; EO sterilizing agent for medical devices will fall under EU Medical Devices Regulation, potentially imposing new and different regulatory requirements.
    Source: SHC 10-K 2025 Risk Factors: 'We may be subject to evolving changes in environmental, health and safety regulations'
  • Russian Co-60 Supply Dependency and Sanctions Risk. Company estimates ~20% of long-term Co-60 supply from Russian nuclear reactors; could increase to ~50% in given years due to outages elsewhere. U.S., Canada, UK, and EU sanctions against Russia threaten supply. Banks previously used to pay suppliers have been sanctioned. Licenses for ocean carrier transporting Co-60 from Russia to North America, CNSC licenses for Canadian Co-59 targets, expire 2026–2028. January 2026: Complaint filed in U.S. District Court seeking to invalidate two-year sterilization facility exemption, which could force immediate NESHAP compliance.
    Source: SHC 10-K 2025 Risk Factors: 'We depend on a limited number of counterparties to provide the materials and resources we need to operate our business'

Disclosed initiatives

  • EO Emission Control Enhancements
    Company has made proactive, voluntary investments to enhance emissions controls and employee protections at EO facilities. Committed to comply with 2024 EPA NESHAP final rule requiring higher efficiencies for EO emission controls, permanent total enclosure capture technology, and CEMS (Continuous Emission Monitoring Systems). Two-year compliance exemption granted July 2025.
    Reduces near-term operational EO emissions; compliance timeline extended to 2027 under exemption.
  • Participation in FDA Sterilization Alternative Initiatives
    Company has taken part in FDA initiatives to encourage development of sterilization alternatives to EO processing, including vaporized hydrogen peroxide approved as Category-A methodology in 2024.
    Positions company for potential technology diversification but uncertain commercial viability.
  • Co-60 Supply Chain Diversification
    Company sources Co-60 from three nuclear reactor operators and six reactor sites in Canada and Russia under contracts extending to 2026–2064. Approximately 20% from Russian reactors, with flexibility to obtain from other sources.
    Mitigates single-source risk but does not address inherent carbon/nuclear waste profile of Co-60 production.

Social story

Sotera Health's social profile reflects a mid-range score driven by limited workforce diversity disclosure, no evidence of active union suppression, and absence of documented major strikes in the past 24 months. However, the company provides minimal transparency on CEO-to-worker pay ratios, leadership diversity percentages, or supply-chain human-rights audits. The company faces material occupational safety risks related to EO and Co-60 handling; the 10-K references workforce injuries and property damage at facilities, though specific injury rates are not disclosed. Labor unionization efforts are listed as a risk factor, but no active suppression activities, NLRB complaints, or strikes are documented in available filings. The company maintains 'ability to attract and retain qualified employees' as a stated dependency and competitive advantage, but provides no specific retention rates, pay-equity commitments, or diversity targets. Supply-chain human-rights exposure is minimal given the company's focus on service delivery (sterilization and lab testing) rather than mining or sourcing of conflict minerals, though Co-59 target procurement and international operations in Brazil, Mexico, Costa Rica, and Asia warrant review. Overall, the social score reflects absence of disclosed negative indicators combined with limited affirmative ESG commitments or transparency.

Criticisms on file

  • Workforce Injuries and Safety Incidents. 10-K discloses that 'members of our workforce have been injured in our facilities and we have experienced property damage, production disruptions and temporary facility closures.' Company faces workers' compensation claims relating to potentially hazardous materials (EO, Co-60). Specific injury rates, OSHA violations, or safety citations not disclosed in filing.
    Source: SHC 10-K 2025 Risk Factors: 'Safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials'
  • Hazardous Material Handling – Occupational Exposure Risk. EO is flammable and explosive under certain conditions; Co-60 presents radioactive contamination risk. Employees must handle these materials safely; accidents resulting from employee failure to follow safety protocols could result in injury. Company discloses reliance on employee compliance but does not quantify safety metrics, incident rates, or near-miss statistics.
    Source: SHC 10-K 2025 Risk Factors: 'Safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials'
  • International Operations – Labor and Regulatory Compliance Risk. Company operates in countries (Brazil, Mexico, Costa Rica, China, Asia) with varying labor standards and anti-corruption enforcement. Risk of violations by employees or third parties despite internal policies. No specific human-rights audit, forced-labor policy, or living-wage commitment disclosed.
    Source: SHC 10-K 2025 Risk Factors: 'We conduct sales and distribution operations on a worldwide basis and are subject to a variety of risks associated with doing business outside the United States'

Disclosed initiatives

  • Occupational Health and Safety Enhancements at EO Facilities
    Company has made investments to enhance employee protections at EO facilities, including heightened worker protection practices, facility design improvements, employee exposure monitoring, and training. FIFRA ID requirements mandate reduced EO exposure levels, implementation of worker protection practices in non-respiratory areas, cycle concentration limits, and additional monitoring.
    Reduces occupational health risk from EO exposure; compliance timelines specified in regulatory framework.
  • Global Code of Conduct
    Company has established Global Code of Conduct governing employee and agent conduct, including anti-corruption compliance (FCPA, CFPOA, UK Bribery Act). Employees and agents required to comply with applicable laws and internal policies.
    Establishes ethical baseline; specific labor-rights, living-wage, or diversity commitments not disclosed in filing.

Governance story

Sotera Health's governance score reflects mixed performance across board independence, share structure, and regulatory compliance. The company operates under a standard single-class share structure with no disclosed dual-class voting arrangements, supporting a higher baseline governance score. However, detailed board composition and independence percentage are not disclosed in the 10-K excerpt provided, preventing precise scoring on the 75% independence threshold. The company does not appear to engage in aggressive climate-deregulation or consumer-protection lobbying based on available disclosures, though specific annual lobbying expenditures are not quantified in the filing. Material governance concerns include: (1) ongoing EO tort litigation ($472.9M in settlements 2023–2025) and regulatory non-compliance history, which may trigger antitrust, consumer-safety, or environmental enforcement proceedings; (2) control by Warburg Pincus and GTCR private-equity sponsors, flagged as a risk factor for ongoing founder/sponsor voting control; (3) substantial litigation costs ($46.2M in 2025 professional fees) and contingent liabilities; (4) no disclosed consent decrees, SEC enforcement actions, or material antitrust proceedings evident, but EO litigation settlements and regulatory scrutiny represent de facto governance failures. The absence of disclosed shareholder proposals, board compensation practices, or executive-session protocols further limits governance transparency. Deduction applied for founder/sponsor control concentration risk.

Criticisms on file

  • Ethylene Oxide Litigation and Regulatory Non-Compliance History. Multi-state tort litigation (CA, GA, IL, NM) with $472.9M in settlements (2023–2025) and ongoing pending claims indicate systemic governance failures in environmental compliance and risk management. Company denies allegations; however, pattern of settlements, regulatory injunctions (Santa Teresa, NM), and community resistance suggests regulatory and reputational governance risk.
    Source: SHC 10-K 2025; Note 19 Commitments and Contingencies; Item 3 Legal Proceedings
  • EPA NESHAP Regulatory Exemption Challenge. January 2026: U.S. District Court complaint filed against President, U.S. EPA, and EPA Administrator seeking to invalidate July 2025 two-year exemption for sterilization facilities. If exemption invalidated, company must comply with original NESHAP rule by April 2026, creating material operational and compliance risk.
    Source: SHC 10-K 2025 Risk Factors: 'We may be subject to evolving changes in environmental, health and safety regulations'
  • Sponsor Control and Minority Shareholder Rights. Warburg Pincus and GTCR sponsors retain material control over company; risk factor notes ongoing sponsor control as potential adverse factor for minority shareholders. No disclosed governance mechanisms to balance sponsor interests with minority protections.
    Source: SHC 10-K 2025 Risk Factor Summary: 'the control that certain investment funds and entities affiliated with Warburg Pincus and GTCR continue to have over us'
  • Contingent Liabilities and Financial Assurance Requirements. Company maintains $50.3M in financial assurance (letters of credit, surety bonds) for Co-60 radiological decommissioning liabilities. Future decommissioning costs may exceed current estimates if additional facilities licensed, contamination occurs, or regulatory requirements change. Material financial governance risk.
    Source: SHC 10-K 2025 Risk Factors: 'We are subject to extensive regulatory requirements and routine regulatory audits in our operations'
  • Insurance Coverage Gaps and Self-Insured Retention. Current pollution liability insurance excludes coverage for EO claims. Product and professional liability insurance does not cover EO emissions. Company subject to significant self-insured retention amounts, limiting insurer recovery. Material governance failure in risk transfer.
    Source: SHC 10-K 2025 Risk Factors: 'We are currently defending certain litigation, and we are likely to be subject to additional litigation in the future'

Disclosed initiatives

  • Regulatory Compliance and Licensing Framework
    Company maintains extensive compliance with FDA, NRC, EPA, OSHA, and international regulatory agencies. Holds multiple permits, licenses, and approvals for operation of sterilization and lab facilities. Undergoes routine regulatory audits and Form 483 findings from FDA.
    Establishes baseline compliance infrastructure; however, historical litigation and ongoing regulatory scrutiny indicate effectiveness limitations.
  • Internal Control Over Financial Reporting
    Company maintains systems and procedures to ensure effective internal control over financial reporting. Risk factor acknowledges 'ability to maintain effective internal control over financial reporting' as ongoing management objective.
    Standard corporate governance practice; no disclosed material weaknesses or management changes evident in filing.
  • Anti-Corruption Compliance (FCPA, CFPOA, UK Bribery Act)
    Company policy requires employees and agents to comply with U.S. Foreign Corrupt Practices Act, Canadian Corruption of Foreign Public Officials Act, and UK Bribery Act. Employees in jurisdictions with varying anti-corruption standards subject to internal policy enforcement.
    Establishes anti-corruption baseline; detection, investigation, and resolution of violations noted as costly and time-consuming.
  • Data Privacy and Cybersecurity Governance
    Company subject to evolving data privacy and security laws and regulations across multiple jurisdictions. Risk factor notes 'ability to comply with rapidly evolving data privacy and security laws and regulations' as management priority.
    Reactive governance posture; no proactive privacy certifications, third-party audits, or security frameworks disclosed.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Sotera Health Company. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Sotera Health Company in the app for interactive charts and portfolio building.

Open Sotera Health Company in Missionomics

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)

Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics